Buruli ulcer disease: Prospects for a vaccine

Medical Microbiology and Immunology

Volumn 198, Issue 2, 2009, Pages 69-77

  Huygen, Kris ^a   Adjei, Ohene ^b   Affolabi, Dissou ^c   Bretzel, Gisela ^d   Demangel, Caroline ^e   Fleischer, Bernhard ^f   Johnson, Roch Christian ^g   Pedrosa, Jorge ^h   Phanzu, Delphin M ⁱ   Phillips, Richard O ^j   Pluschke, Gerd ^k   Siegmund, Vera ^l   Singh, Mahavir ^m   Van Der Werf, Tjip S ⁿ   Wansbrough Jones, Mark ^o   Portaels, Françoise ^p  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b KUMASI CENTRE FOR COLLABORATIVE RESEARCH IN TROPICAL MEDICINE   (Ghana)

^c Laboratoire de Référence des Mycobactéries   (Benin)

^d UNIVERSITY OF MUNICH   (Germany)

^e INSTITUT PASTEUR   (France)

^f BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^g Programme National de Lutte Contre l'Ulcere de Buruli   (Benin)

^h UNIVERSITY OF MINHO   (Portugal)

ⁱ Institut Médical Evangélique   (Congo)

^j KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^k SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^l European Research and Project Office GmbH   (Germany)

^m LIONEX DIAGNOSTICS AND THERAPEUTICS GMBH   (Germany)

ⁿ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^o ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^p INSTITUTE OF TROPICAL MEDICINE   (Belgium)

more..

Author keywords

Buruli ulcer; Mycobacterium ulcerans; Mycolactone toxin; Neglected diseases; Review; Vaccine

Indexed keywords

BCG VACCINE; CLOFAZIMINE; PLACEBO; STREPTOMYCIN;

ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; BACTERIAL INFECTION; BCG VACCINATION; BURULI ULCER; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; INFECTION RISK; MYCOBACTERIUM ULCERANS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RURAL AREA; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT FAILURE; TUBERCULOSIS; VACCINATION;

AFRICA, WESTERN; BACTERIAL VACCINES; BURULI ULCER; HUMANS; INCIDENCE; MYCOBACTERIUM ULCERANS; PREVALENCE;

EID: 67349151300     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00430-009-0109-6     Document Type: Review

References (71)

1. S Adusumilli A Mve-Obiang T Sparer W Meyers J Hayman PLC Small 2005 Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo Cell Microbiol 7 1295 1304 10.1111/j.1462-5822.2005.00557.x (Pubitemid 41179422)
2. I Aujoulat MP Huguet-Ribas Y Koita 1996 Buruli ulcer: an ignored public health problem Dev Sante 125 22 30 (in French)
3. GM Bahr TD Chugh K Behbehani MA Shaaban M Abdul-Aty B Al Shimali Z Siddiqui M Gabriel GA Rook JL Stanford 1987 Unexpected findings amongst the skin test responses to mycobacteria of BCG vaccinated Kuwaiti school children Tubercle 68 105 10.1016/0041-3879(87)90025-0 (Pubitemid 17099433)
4. JT Belisle VD Vissa T Sievert K Takayama BJ Brennan GS Besra 1997 Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis Science 276 1420 14222 10.1126/science.276.5317.1420 (Pubitemid 27235411)
5. Buntine J, Crofts K (eds) (2001) Buruli ulcer: management of Mycobacterium ulcerans disease. World Health Organization, Geneva
6. A Chauty MF Ardant A Adeye H Euverte A Guédénon C Johnson J Aubry E Nuermberger J Grosset 2007 Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease) Antimicrob Agents Chemother 51 4029 4035 10.1128/AAC.00175-07 (Pubitemid 350057802)
7. Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P et al (2005) Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol 7:1187-1196. doi: 10.1111/j.1462-5822.2005.00546.x
8. E Coutanceau P Legras L Marsollier G Reysset ST Cole C Demangel 2006 Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer Microbes Infect 8 2075 2081 10.1016/j.micinf.2006.03.009 (Pubitemid 44311577)
9. E Coutanceau J Decalf A Martino A Babon N Winter 2007 Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone J Exp Med 204 1395 1403 10.1084/jem.20070234 (Pubitemid 46919877)
10. M Debacker C Zinsou J Aguiar WM Meyers F Portaels 2003 First case of Mycobacterium ulcerans disease (Buruli Ulcer) that followed a human bite Clin Infect Dis 36 e67 e68 10.1086/367660
11. Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Scott JT, Dramaix M, Portaels F (2004) Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health 9(12) 1297-1304
12. M Debacker J Aguiar C Steunou C Zinsou WM Meyers F Portaels 2005 Buruli ulcer recurrence, Benin Emerg Infect Dis 11 584 589 (Pubitemid 40462909)
13. M Debacker F Portaels J Aguiar C Steunou C Zinsou W Meyers M Dramaix 2006 Risk factors for Buruli ulcer, Benin Emerg Infect Dis 12 1325 1331 (Pubitemid 44455207)
14. C Demangel TP Stinear ST Cole 2009 Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans Nat Rev Microbiol 7 50 60 10.1038/nrmicro2016
15. D Diaz H Dobeli D Yeboah-Manu E Mensah-Quainoo A Friedlein 2006 Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans Clin Vaccine Immunol 13 1314 1321 10.1128/CVI.00254-06 (Pubitemid 46086896)
16. KM Dobos EA Spotts BJ Marston CR Horsburgh Jr CH King 2000 Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease Emerg Infect Dis 6 158 164 (Pubitemid 30226893)
17. KM George D Chatterjee G Gunawardana D Welty J Hayman R Lee PL Small 1999 Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence Science 283 854 857 10.1126/science.283.5403.854 (Pubitemid 29072327)
18. TM Gooding PDR Johnson DE Campbell JA Hayman E Hartland AS Kemp RM Robins-Browne 2001 Immune response to infection with Mycobacterium ulcerans Infect Immun 69 1704 1707 10.1128/IAI.69.3.1704-1707.2001 (Pubitemid 32187628)
19. TM Gooding PD Johnson M Smith AS Kemp RM Robins-Browne 2002 Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts Infect Immun 70 5562 5567 10.1128/IAI.70.10.5562-5567.2002
20. TM Gooding AS Kemp RM Robins-Browne M Smith PD Johnson 2003 Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans Clin Infect Dis 36 1076 1077 10.1086/368315 (Pubitemid 36513296)
21. KP Grietens A Um Boock H Peeters S Hausmann-Muela E Toomer JM Ribera 2008 It is me who endures but my family that suffers: social isolation as a consequence of the household cost burden of Buruli ulcer free of charge hospital treatment PLoS Negl Trop Dis 2 e321 10.1371/journal.pntd.0000321
22. J Hayman 1993 Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection J Clin Pathol 46 5 9 10.1136/jcp.46.1.5 (Pubitemid 23039578)
23. H Hong C Demangel SJ Pidot PF Leadlay T Stinear 2008 Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria Nat Prod Rep 25 447 454 10.1039/b803101k
24. H Hong E Coutanceau M Leclerc L Caleechurn PF Leadlay C Demangel 2008 Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs PLoS Negl Trop Dis 2 e325 10.1371/journal.pntd.0000325
25. K Huygen 2003 Prospects for vaccine development against Buruli disease Expert Rev Vaccines 2 561 569 10.1586/14760584.2.4.561 (Pubitemid 36988486)
26. RC Johnson GE Sopoh M Boko C Zinsou J Gbovi M Makoutode F Portaels 2005 Distribution de l'infection à Mycobacterium ulcerans (ulcère de Buruli) dans la commune de Lalo au Bénin Trop Med Int Health 10 863 871 10.1111/j.1365-3156.2005.01465.x (Pubitemid 41291226)
27. AE Kiszewski E Becerril LD Aguilar IT Kader WM Meyers F Portaels PR Hernandez 2006 The local immune response in ulcerative lesions of Buruli disease Clin Exp Immunol 143 445 451 10.1111/j.1365-2249.2006.03020.x
28. V Lagarrigue F Portaels WM Meyers J Aguiar 2000 Buruli ulcer: risk of bone involvement! A propos of 33 cases observed in Benin Med Trop 60 262 266
29. P Launois R DeLeys MN Niang A Drowart M Andrien P Dierckx JL Cartel JL Sarthou JP Van Vooren K Huygen 1994 T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy Infect Immun 62 3679 3687
30. L Marsollier R Robert J Aubry 2002 Aquatic insects as a vector for Mycobacterium ulcerans Appl Environ Microbiol 68 4623 4628 10.1128/AEM.68.9. 4623-4628.2002
31. BJ Marston MO Diallo CR Horsburgh Jr I Diomande MZ Saki JM Kanga G Patrice HB Lipman SM Ostroff RC Good 1995 Emergence of Buruli ulcer disease in the Daloa region of Cote d'Ivoire Am J Trop Med Hyg 52 219 224
32. N Mor I Lutsky L Levy 1981 Response in the hindfoot pad and popliteal lymph node of C57BL mice to infection with Mycobacterium marinum Isr J Med Sci 17 236 244
33. F Nackers RC Johnson J Glynn C Zinsou R Tonglet F Portaels 2007 Environmental and health-related risk factors for Mycobacterium ulcerans disease (Buruli ulcer) in Benin Am J Trop Med Hyg 77 834 836
34. J Noeske C Kuaban S Rondini P Sorlin L Ciaffi J Mbuagbaw F Portaels G Pluschke 2004 Buruli ulcer disease in Cameroon rediscovered Am J Trop Med Hyg 70 520 526
35. DM Okenu LO Ofielu KA Easley J Guarner EA Spotts Whitney 2004 Immunoglobulin M antibody responses to Mycobacterium ulcerans allow discrimination between cases of active Buruli ulcer disease and matched family controls in areas where the disease is endemic Clin Diagn Lab Immunol 11 387 391 10.1128/CDLI.11.2.387-391.2004
36. MS Oliveira AG Fraga E Torrado AG Castro JP Pereira AL Filho F Milanezi FC Schmitt WM Meyers F Portaels MT Silva J Pedrosa 2005 Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice Infect Immun 73 6299 6310 10.1128/IAI.73.10.6299-6310.2005
37. AA Pahlevan DJ Wright G Andrews KM George PL Small 1999 The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function J Immunol 163 3928 3935
38. R Phillips C Horsfield JA Mangan K Laing S Etuaful P Awuah K Nyarko F Osei-Sarpong P Biutcehr S Lucas M Wansbrough-Jones 2006 Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response Infect Immun 74 2917 2924 10.1128/IAI.74.5.2917-2924.2006
39. F Portaels P Elsen A Guimaraes-Peres P-A Fonteyne WM Meyers 1999 Insects in the transmission of Mycobacterium ulcerans infection (Buruli ulcer) Lancet 353 986 10.1016/S0140-6736(98)05177-0
40. Portaels F, Chemlal K, Elsen P, Johnson PDR, Hayman JA, Kirkwood R, Meyers WM (2001) Mycobacterium ulcerans in wild animals. In: Collins MT, Manning B (eds) Mycobacterial infections in domestic and wild animals. Office International de Epizooties, vol 20. Scientific and Technical Review, Paris, pp 252-264
41. Portaels F, Johnson P, Meyers WM (eds) (2001) Buruli ulcer: diagnosis of Mycobacterium ulcerans disease. World Health Organization, Geneva
42. F Portaels J Aguiar M Debacker C Steunou C Zinsou A Guédé non WM Meyers 2002 Prophylactic effect of Mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer) Clin Diagn Lab Immunol 9 1389 1391 10.1128/CDLI.9.6.1389-1391.2002
43. F Portaels J Aguiar M Debacker A Guédénon C Steunou C Zinsou WM Meyers 2004 BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli Ulcer disease Infect Immun 72 62 65 10.1128/IAI.72.1.62-65.2004
44. F Portaels WM Meyers A Ablordey A Castro K Chemlal P De Rijk P Elsen K Fissette A Fraga R Lee E Mahrous P Small P Stragier E Torrado A Van Aerde M Texeira da Silva J Pedrosa 2008 First cultivation and characterization of Mycobacterium ulcerans from the environment PLoS Negl Trop Dis 2 e178 10.1371/journal.pntd.0000178
45. Portaels F, Silva MT, Meyers WM (2009) Buruli ulcer. Clin Dermatol (in press)
46. R Pouillot G Matias C Mbondji Wondje F Portaels N Valin F Ngoss A Njikap L Marsollier A Fontanet S Eyangoh 2007 Risk factors for Buruli ulcer disease in Cameroon PLoS Negl Trop Dis 1 e101 10.1371/journal.pntd.0000101
47. G Prévot E Bourreau H Pascalis R Pradinaud A Tanghe K Huygen P Launois 2004 Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease Infect Immun 72 958 965 10.1128/IAI.72.2.958-965.2004
48. TY Quek E Athan MJ Henry JA Pasco J Redden-Hoare A Hughes PD Johnson 2007 Risk factors for Mycobacterium ulcerans infection, southeastern Australia Emerg Infect Dis Nov 13 11 1661 1666
49. Revill WD, Morrow RH, Pike MC, Ateng J (1973) A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 2: 873-877, 95
50. V Siegmund O Adjei J Nitschke W Thompson E Klutse KH Herbinger R Thompson F van Vloten P Racz B Fleischer T Loescher G Bretzel 2007 Dry reagent-based polymerase chain reaction compared with other laboratory methods available for the diagnosis of Buruli ulcer disease Clin Infect Dis 45 68 75 10.1086/518604
51. MF Silva F Portaels J Pedrosa 2007 Aquatic insects and Mycobacterium ulcerans: an association relevant to Buruli ulcer control? PLoS Med 4 e63 10.1371/journal.pmed.0040063
52. PG Smith WDL Revill E Lukwago YP Rykushin 1976 The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda Trans R Soc Trop Med Hyg 70 449 457 10.1016/0035-9203(76)90128-0
53. JL Stanford WD Revill WJ Gunthorpe JM Grange 1975 The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection J Hyg (Lond) 74 7 16
54. Y Stienstra WT Van Der Graaf GJ te Meerman TH The LF de Leij TS van der Werf 2001 Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors Trop Med Int Health 6 554 562 10.1046/j.1365-3156.2001.00746.x
55. TP Stinear GA Jenkin PD Johnson JK Davies 2000 Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence J Bacteriol 182 6322 6330 10.1128/JB.182.22.6322-6330.2000
56. TP Stinear A Mve-Obiang PLC Small W Frigui MJ Pryor R Brosch GA Jenkin PDR Johnson JK Davies RE Lee S Adusumilli T Garnier SF Haydock PF Leadlay ST Cole 2004 Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans Proc Natl Acad Sci USA 101 1345 1349 10.1073/pnas.0305877101
57. A Tanghe J Content JP Van Vooren F Portaels K Huygen 2001 Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer Infect Immun 69 5403 5411 10.1128/IAI.69.9.5403-5411.2001
58. A Tanghe PY Adnet T Gartner K Huygen 2007 A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice Infect Immun 75 2642 2644 10.1128/IAI.01622-06
59. A Tanghe J-P Danzy G Pluschke K Huygen 2008 Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting PLoS Negl Trop Dis 2 e199 10.1371/journal.pntd.0000199
60. T Tonjum DB Welty E Jantzen PL Small 1998 Differentiation of Mycobacterium ulcerans, M. marinum, and M. haemophilum: mapping of their relationships to M. tuberculosis by fatty acid profile analysis, DNA-DNA hybridization, and 16S rRNA gene sequence analysis J Clin Microbiol 36 918 925
61. E Torrado S Adusumilli AG Fraga PL Small AG Castro 2007 Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection Infect Immun 75 3979 3988 10.1128/IAI.00290-07
62. Uganda Buruli Group (1969) Lancet 18th, 111
63. TS Van der Werf WT Van der Graaf JW Tappero K Asiedu 1999 Mycobacterium ulcerans infection Lancet 354 1013 1018 10.1016/S0140-6736(99)01156-3
64. JP Van Vooren A Drowart J De Bruyn P Launois J Millan E Delaporte M Develoux JC Yernault K Huygen 1992 Humoral responses against the 85A and 85B antigens of Mycobacterium bovis BCG in patients with leprosy and tuberculosis J Clin Microbiol 30 1608 1610
65. DS Walsh WM Meyers FP Portaels JE Lane D Mongkolsirichaikul K Hussem P Gosi KS Myint 2005 High rates of apoptosis in human Mycobacterium ulcerans culture-positive buruli ulcer skin lesions Am J Trop Med Hyg 73 410 415
66. BD Westenbrink Y Stienstra MG Huitema WA Thompson EO Klutse EO Ampadu HM Boezen PC Limburg TS Van der Werf 2005 Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana Clin Diagn Lab Immunol 12 125 129 10.1128/CDLI.12.1.125-129.2005
67. HG Wiker M Harboe 1992 The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis Microbiol Rev 56 648 661
68. World Health Organization (2000) Buruli ulcer. In: Asiedu K, Scherpbier R, Raviglione M (eds) Mycobacterium ulcerans infection. World Health Organization, Geneva
69. World Health Organization (2004) Provisional guidance on the role specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). World Health Organization, Geneva
70. World Health Organization 2008 Buruli ulcer disease. Mycobacterium ulcerans infection: an overview of reported cases globally Wkly Epidemiol Rec 83 145 156
71. D Yeboah-Manu E Peduzzi E Mensah-Quainoo A Asante-Poku D Ofori-Adjei 2006 Systematic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans J Leukoc Biol 79 1150 1156 10.1189/jlb.1005581